Garcia-Pachon Eduardo, Soler-Sempere María J, Zamora-Molina Lucia, Baeza-Martinez Carlos, Grau-Delgado Justo, Padilla-Navas Isabel
Clin Lab. 2020 Aug 1;66(8). doi: 10.7754/Clin.Lab.2020.191267.
Efforts have been made to search for parameters that facilitate the prediction of the 3-month survival for clinical decisions in patients with malignant pleural effusion (MPE). We sought to evaluate whether the platelet-to-lymphocyte ratio (PLR) may be a useful marker of 3-month survival in a series of consecutive patients with MPE.
A total of 81 patients with MPE were included, 46 (57%) of whom were female. Twenty-six patients (32%) died during the first 3 months according to thoracentesis data.
The area under the receiver operating characteristics curve was 0.73 for PLR. Using a cutoff point of 158, patients with higher PLR values experienced higher mortality at 3 months (p = 0.001).
PLR was able to successfully differentiate patients with different survival at 3 months. Outcomes of the PLR (a fast and inexpensive test) could be included among the prognostic factors able to guide the personalized management of MPE.
人们一直在努力寻找有助于预测恶性胸腔积液（MPE）患者3个月生存率以用于临床决策的参数。我们试图评估血小板与淋巴细胞比值（PLR）是否可能是一系列连续性MPE患者3个月生存率的有用标志物。
共纳入81例MPE患者，其中46例（57%）为女性。根据胸腔穿刺数据，26例患者（32%）在最初3个月内死亡。
PLR的受试者工作特征曲线下面积为0.73。使用158作为临界值，PLR值较高的患者在3个月时死亡率更高（p = 0.001）。
PLR能够成功区分3个月时具有不同生存率的患者。PLR（一种快速且廉价的检测方法）的结果可纳入能够指导MPE个性化管理的预后因素之中。
